Sign In
Buy MREO
$0.334
-0.0052 (-1.53%)
At Close: Jun 03, 2026
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
12:00pm, Monday, 07'th Oct 2019
LONDON and REDWOOD CITY, Calif., Oct. 07, 2019 -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company" or the "Group," a clinical stage.
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update
11:00am, Tuesday, 17'th Sep 2019
12-Month Topline Results from Phase 2b ASTEROID Study with Setrusumab for Osteogenesis Imperfecta (OI) Expected in Q4 2019; Positive 6-Month Data to be Featured in Late-Breaking.
LONDON and REDWOOD CITY, Calif., Sept. 10, 2019 -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage.
LONDON and REDWOOD CITY, Calif., Sept. 04, 2019 -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage.
Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development
12:00pm, Tuesday, 16'th Jul 2019
LONDON and REDWOOD CITY, Calif., July 16, 2019 -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on rare diseases, today.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW.
How Do Analysts See Mereo BioPharma Group plc (LON:MPH) Performing In The Next Couple Of Years?
12:29pm, Tuesday, 25'th Jun 2019
Mereo BioPharma Group plc's (LON:MPH) latest earnings announcement in April 2019 confirmed that losses became smaller...
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • A
